Literature DB >> 3292147

Effect of treatment with recombinant human erythropoietin on peripheral hemodynamics and oxygenation.

B Nonnast-Daniel1, A Creutzig, K Kühn, J Bahlmann, E Reimers, R Brunkhorst, L Caspary, K M Koch.   

Abstract

Slow progressive improvement of renal anemia from 21 up to 33% hematocrit by rhEPO treatment results in an increase of tissue oxygenation as indicated by a rise of the transcutaneous oxygen pressure. In normotensive patients this was accompanied by an increase in MAP (delta 6 mm Hg) within the normal range and a significant fall of the regional blood flow. These hemodynamic changes are caused by increases of the regional and presumably also of the total peripheral vascular resistance. Most likely the increase in total peripheral vascular resistance represents an autoregulatory event triggered by the rising tissue oxygenation. From the present data it is difficult to estimate to what extent the observed rise in hematocrit affects peripheral vascular resistance also via an increase of blood viscosity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3292147     DOI: 10.1159/000416017

Source DB:  PubMed          Journal:  Contrib Nephrol        ISSN: 0302-5144            Impact factor:   1.580


  5 in total

1.  Treatment of the anaemia of chronic renal failure with recombinant human erythropoietin.

Authors:  C G Winearls
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

Review 2.  The use of erythropoietin in renal failure.

Authors:  I C Macdougall; R D Hutton; G A Coles; J D Williams
Journal:  Postgrad Med J       Date:  1991-01       Impact factor: 2.401

Review 3.  [Erythropoietin and hypertension].

Authors:  U Frei; B Nonnast-Daniel; K M Koch
Journal:  Klin Wochenschr       Date:  1988-09-15

4.  Chronic administration of small nonerythropoietic peptide sequence of erythropoietin effectively ameliorates the progression of postmyocardial infarction-dilated cardiomyopathy.

Authors:  Ismayil Ahmet; Hyun-Jin Tae; Michael Brines; Anthony Cerami; Edward G Lakatta; Mark I Talan
Journal:  J Pharmacol Exp Ther       Date:  2013-04-12       Impact factor: 4.030

5.  Acute hemodynamic effects of erythropoietin do not mediate its cardioprotective properties.

Authors:  Ismayil Ahmet; Edward G Lakatta; Mark I Talan
Journal:  Biol Open       Date:  2012-08-22       Impact factor: 2.422

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.